All In Biotech

Drug Trial Radar · NCT06357221

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

A Multi-center, Open-label, In-use Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

46

Actual

Start

Apr 8, 2024

Primary completion

Jul 18, 2024

Study completion Jul 18, 2024

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Apr 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen's efficacy will be conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.

Conditions

  • Plaque Psoriasis
  • Psoriasis

Interventions

  • CetaphilDrug

    Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Psoriatic Body Surface Area Compared to BaselineTime frame: Baseline, Week 2, Week 4, Week 8
  2. Change in Target Lesion Severity Compared to BaselineTime frame: Baseline, Week 2, Week 4, Week 8
  3. Change of Physician Global Assessment Compared to BaselineTime frame: Baseline, Week 2, Week 4, Week 8
  4. Change in Skin Scaliness Measured by Macroscopic ImagingTime frame: Baseline, Week 2, Week 4, Week 8
  5. Change in Skin Smoothness Measured by Macroscopic ImagingTime frame: Baseline, Week 2, Week 4, Week 8
  6. Subject Treatment SatisfactionTime frame: Week 2
  7. Subject Treatment SatisfactionTime frame: Week 4
  8. Subject Treatment SatisfactionTime frame: Week 8
  9. Changes in Dryness Compared to Baseline [Tolerability Assessment]Time frame: Baseline, Week 2, Week 4, Week 8
  10. Change in Burning/Stinging Compared to Baseline [Tolerability Assessment]Time frame: Baseline, Week 2, Week 4, Week 8
  11. Change in Itching Compared to Baseline [Tolerability Assessment]Time frame: Baseline, Week 2, Week 4, Week 8

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Southeast Dermatology Specialists, LLC

    Columbus, Georgia

  • Southeast Dermatology Specialists, LLC

    Douglasville, Georgia

  • Dermatology Consulting Services

    High Point, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.